Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
VRCA
Strong SellSinkerVerrica Pharmaceuticals Inc. · Healthcare · United States · $98M · Avg Vol: $439K/d
7
StockRankGet insider-trade alerts
Q
29
V
25
M
23
P/E (TTM)
—
ROE
-72.3%
D/E
0.4x
Dividend %
—
COMPANY DESCRIPTION
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.0M | 5.1M | 7.6M | 35.6M | 57.9% | 30.3M | 24.8M | 39.2M | 5.0% |
| EPS | -1.72 | -3.65 | -14.80 | -1.68 | — | -1.72 | -1.97 | -1.48 | — |
| Shares | 17.2M | 17.2M | 9.2M | 17.2M | 0.0% | 17.2M | — | — | — |
| Debt | 1.5M | 45.5M | 45.9M | 1.6M | 2.2% | 1.8M | — | — | — |
| Equity | 40.0M | 19.8M | -9.9M | 24.7M | -14.8% | — | — | — | — |
| Op CF | -18.6M | -38.6M | -60.9M | -17.6M | — | -13.3M | — | — | — |
| Inv CF | 54.0M | -0.4M | -19.0K | 0 | — | — | — | — | — |
| Fin CF | -16.9M | 74.2M | 37.7M | 1.4M | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)-5.9%
SMA 50SMA 200
Close
$4.95
RSI (14)
52.2
52W High
$9.82
From 52W High
0.5%
SCORE BREAKDOWN
Quality
29
ROIC
-89.4%7.7
ROE
-72.3%13.5
GP/Assets
24.2%52.8
Op. Margin
-194.5%14.2
FCF/Assets
-25.8%16.4
Piotroski
668.7
Int. Cover
-7.4x24.6
D/E Ratio
0.42x32.7
Current Ratio
1.45x25.3
Value
25
P/E (TTM)
—N/A
EV/EBITDA
-3.1x25.0
P/FCF
—N/A
P/B
21.1x5.3
P/S
3.0x56.6
Div Yield
—N/A
Momentum
23
52W High %
50%24.1
RS 6M
-34%25.0
SMA 50/200
0.86x24.2
EPS Rev 4W
-18.8%4.9
EPS Rev 12W
—N/A
EPS Improve
+14%30.5
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$98M
P/E (Forward)
-3.6x
Gross Margin
37.7%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of VRCA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| VRCA | Verrica Pharmaceuticals Inc.(you) | $98M | 7 | Strong Sell |
| KLRS | Kalaris Therapeutics, Inc. | $96M | 7 | Strong Sell |
| PLYX | Polaryx Therapeutics, Inc. | $103M | 5 | Strong Sell |
| DWTX | Dogwood Therapeutics, Inc. | $90M | 9 | Strong Sell |
| RANI | Rani Therapeutics Holdings, Inc. | $118M | 7 | Strong Sell |
| ONCY | Oncolytics Biotech Inc. | $109M | 5 | Strong Sell |
| COYA | Coya Therapeutics, Inc. | $108M | 10 | Strong Sell |
| GANX | Gain Therapeutics, Inc. | $77M | 7 | Strong Sell |
| ALDX | Aldeyra Therapeutics, Inc. | $90M | 4 | Strong Sell |
| CGTX | Cognition Therapeutics, Inc. | $97M | 13 | Strong Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.3%